Calcineurin inhibitors

Dermatologic Therapy

Volumn 15, Issue 4, 2002, Pages 325-332

  Tharp, Michael D ^a  

^a NONE

Author keywords

Bullous pemphigoid; Calcineurin; Cyclosporine A; Pemphigus foliaceus; Pemphigus vulgaris; Pimecrolimus; Tacrolimus

Indexed keywords

ALLOPURINOL; AMIODARONE; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; BROMOCRIPTINE; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CHLOROQUINE; COLCHICINE; CYCLOSPORIN A; DILTIAZEM; FLUCONAZOLE; GLUCOCORTICOID; HORMONE; HYPERICUM PERFORATUM EXTRACT; IMMUNOPHILIN; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PIMECROLIMUS; TACROLIMUS; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ALOPECIA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BLISTER; CONVULSION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; EROSION; FETUS MALFORMATION; GINGIVA HYPERPLASIA; HEADACHE; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOMAGNESEMIA; INFECTION; LYMPHOPROLIFERATIVE DISEASE; MOUTH ULCER; NEPHROTOXICITY; NEUROTOXICITY; PARESTHESIA; REVIEW; SKIN DISEASE; SKIN INFLAMMATION; SYSTEMIC DISEASE; T LYMPHOCYTE ACTIVATION; TREMOR;

EID: 0036966475     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1529-8019.2002.01541.x     Document Type: Review

References (42)

1. Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin. An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral) in organ transplantation. Drugs 2001; 61: 1958-2016.
2. Letko E, Bhol K, Pinar V, et al. Tacrolimus (Fk506). Ann Allergy Asthma Immunol 1999; 83: 179-190.
3. Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium. Arch Dermatol 1999; 135: 574-580.
4. Cather JC, Abramovits W, Menter A. Cyclosporine and tacrolimus in dermatology. Dermatol Clin 2001; 19: 119-137.
5. Gupta AK, Brown MD, Ellis CN, et al. Cyclosporine Dermatol. J Am Acad Dermatol 1989; 21: 1245-1256.
6. Almawi WY, Melemedjian OK. Clinical and mechanistic differences between FK506 (Tacrolimus) and Cyclosporin a. Nephrol Dial Transplant 2000; 15: 1916-1918.
7. Venkataramanan R, Warty VS, Zemaitis MA, et al. Biopharmaceutical aspects of FK-506. Transplant Proc 1987; 19: 30-35.
8. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281-290.
9. Undre NA, Stevenson P, Schafer A. Pharmacokinetics of tacrolimus: clinical relevant aspects. Transplant Proc 1999; 31(suppl 7A): 21S-24S.
10. Vincent SH, Karanam BV, Painter SK, et al. In vitro metabolism of FK506 in rat, rabbit and human liver microsomes: identification of major metabolite and of cytochrome P450, 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys 1992; 294: 454-460.
11. Schreiber S, Crabtree BR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136-142.
12. De Paulis A, Stellato C, CiriIlo R, et al. Antiinflammatory effect of FK-506 on mast cells. J Invest Dermatol 1992; 99: 723-728.
13. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002; 46: 228-241.
14. Felldin M, Backman L, Brattsstrom C, et al. Rescue therapy with tacrolimus (FK506) in renal transplant recipients - a multicenter analysis. Transplant Proc 1995; 27: 3425.
15. Armitage JM, Kormos RL, Morita S, et al. Clinical trial of FK506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg 1992; 54: 205-211.
16. Feutren JG, Mihatsche MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992; 326: 1654-1660.
17. Lowe NJ, Wielder JM, Rosenbach A, et al. Long-term lowdose cyclosporine therapy for severe psoriasis. Effects on renal function and structure. J Am Acad Dermatol 1996; 35: 710-719.
18. Rossi SJ, Schroeder TJ, Hariharan JS, et al. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Saf 1993; 9: 103-131.
19. Warshaw A, Supran S, Barefoot L, et al. Neoral is associated with less neurotoxicity after liver transplantation (Abstract). Transplantation 1999; 67: S191.
20. Eidelman BH, Abu-Elmagd K, Wilson J, et al. Neurologic complications of FK506. Transplant Proc 1991; 23: 3175-3178.
21. Sperschneider H. A large, multicenter trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation. European Renal Transplantation Study Group. Transplant Proc 2001; 33: 1279-1281.
22. Cockburn I. Assessment of the risks of malignancy and lymphomas developing in patients using Sandimmune. Transplant Proc 1987; 19: 1804-1807.
23. Penn I. Malignancies following the use of cyclosporin A in man. Cancer Surv 1982; 4: 621-624.
24. Penn I. Cancers following cyclosporine therapy. Transplantation 1987; 43: 32-35.
25. Kahan BD. Cyclosporine: the agent and its actions. Transplant Proc 1985; 17: 5-18.
26. Armenti VT, McGrory CH, Cater JR, et al. Pregnancy outcomes in female renal transplant recipients. Transplant Proc 1998; 30: 1732-1734.
27. Zabawski EJ, Costner M, Cohen JB, et al. Tacrolimus. pharmacology and therapeutic uses in dermatology. Int J Dermatol 2000; 39: 721-727.
28. Katz HI. Potential drug interactions with cyclosporine. Int J Dermatol 1997; 36: 18-24.
29. Ellis CN. Safety issues with cyclosporine. Int J Dermatol 1997; 36: 7-10.
30. Cunliffe JW. Pemphigus foliaceus and response to cyclosporin. Br J Dermatol 1987; 117: 114-116.
31. Alijotas J, Pedragosa R, Bosch J, et al. Prolonged remission after cyclosporine therapy in pemphigus vulgaris. report of two young siblings. J Am Acad Dermatol 1990; 23: 701-703.
32. Mobini N, Padilla T Jr, Ahmed AR. Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine. J Am Acad Dermatol 1997; 36: 264-266.
33. Barthelemy H, Frappaz A, Cambazard F, et al. Treatment of nine cases of pemphigus vulgaris with cyclosporine. J Am Acad Dermatol 1988; 18: 1262-1266.
34. Lapidoth M, David M, Ben-Amitai D, et al. The efficacy of combined treatment of prednisone and cyclosporine in patients with pemphigus: preliminary study. J Am Acad Dermatol 1994; 30: 752-757.
35. Ioannides D, Chrysomallis F, Bystryn J-C. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 2000; 136: 868-872.
36. Thivolet J, Barthelemy H, Rigot-Muller JG, et al. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet 1985; 1: 334-335.
37. Merle C, Blanc JD, Zultak M, et al. Intractable epidermolysis bullosa acquisita: efficacy of A cyclosporin. Dermatologica 1990; 181: 44-47.
38. Crow LL, Finkle JP, Gammon RW, et al. Clearing of epidermolysis bullosa acquista with cyclosporine. J Am Acad Dermatol 1988; 19: 937-942.
39. Cunliffe WJ. Bullous pemphigoid and response to cyclosporin. Br J Dermatol 1987; 117: 113-114.
40. Eisen D, Ellis CN. Topical cyclosporine for oral mucosal disorders. J Am Acad Dermatol 1990; 23: 1259-1264.
41. Gooptu C, Staughton RCD. Use of cyclosporin in oral pemphigus. J Am Acad Dermatol 1998; 38: 860-861.
42. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton Syndrome. Arch Dermatol 2001; 137: 747-750.